3I Molecular Solutions And Healthcare Services Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 03-07-2024
- Paid Up Capital ₹ 0.10 M
as on 03-07-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.69 Cr
as on 03-07-2024
- Revenue 16.46%
(FY 2023)
- Profit 96.60%
(FY 2023)
- Ebitda 71.76%
(FY 2023)
- Net Worth 50.42%
(FY 2023)
- Total Assets 98.87%
(FY 2023)
About 3I Molecular Solutions And Healthcare Services
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.69 Cr.
Ajmeer Sheriff and Moutushy Mitra serve as directors at the Company.
- CIN/LLPIN
U74900KA2016PTC086794
- Company No.
086794
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Mar 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at 3I Molecular Solutions And Healthcare Services?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Moutushy Mitra  | Director | 09-Mar-2016 | Current |
| Ajmeer Sheriff | Director | 09-Mar-2016 | Current |
Financial Performance of 3I Molecular Solutions And Healthcare Services.
3I Molecular Solutions And Healthcare Services Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 16.46% increase. The company also saw a substantial improvement in profitability, with a 96.6% increase in profit. The company's net worth Soared by an impressive increase of 50.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of 3I Molecular Solutions And Healthcare Services?
In 2023, 3I Molecular Solutions And Healthcare Services had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Oct 2023 | ₹1.90 M | Open |
Others Creation Date: 03 Jan 2023 | ₹1.50 Cr | Open |
How Many Employees Work at 3I Molecular Solutions And Healthcare Services?
Unlock and access historical data on people associated with 3I Molecular Solutions And Healthcare Services, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of 3I Molecular Solutions And Healthcare Services, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped 3I Molecular Solutions And Healthcare Services's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
